Reportlinker Adds Brazil In Vitro Diagnostics Market Outlook to 2016

NEW YORK, Aug. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Brazil In Vitro Diagnostics Market Outlook to 2016

http://www.reportlinker.com/p0254509/Brazil-In-Vitro-Diagnostics-Market-Outlook-to-2016.html

Netherlands In Vitro Diagnostics Market Outlook to 2016

Summary

GlobalData's new report, "Netherlands In Vitro Diagnostics Market Outlook to 2016" provides key market data on the Netherlands In Vitro Diagnostics (IVD) market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within seven market categories – clinical chemistry, genetic testing, histology and cytology, immuno chemistry, infectious immunology, microbiology culture, and haematology. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

- Market size and company share data for In Vitro Diagnostics (IVD) market categories – clinical chemistry, genetic testing, histology and cytology, immuno chemistry, infectious immunology, microbiology culture, and haematology.

- Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within seven market categories. Data from 2002 to 2009, forecast forward for 7 years to 2016.

- 2009 company shares and distribution shares data for each of the seven market categories.

- Global corporate-level profiles of key companies operating within the Netherlands In Vitro Diagnostics (IVD) market.

- Key players covered include Roche, Siemens Healthcare, Abbott, Beckman Coulter, Biomerieux, Ortho-Clinical Diagnostics, and Becton, Dickinson.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.

- Develop market-entry and market expansion strategies.

- Design competition strategies by identifying who-stands-where in the Netherlands In Vitro Diagnostics (IVD) competitive landscape.

- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.

- What are the key distribution channels and what's the most preferred mode of product distribution – Identify, understand and capitalize.

Table of Contents

1 Table of Contents 2

1.1 List of Tables 9

1.2 List of Figures 12

2 Introduction 15

2.1 What is This Report About? 15

3 In Vitro Diagnostics In Netherlands 16

3.1 3.1 In Vitro Diagnostics, Market Segmentation 16

3.2 In Vitro Diagnostics, Netherlands, Overall Revenue ($m), 2002-2016 17

3.3 In Vitro Diagnostics Market, Netherlands, Revenue Mix ($m), 2009 19

3.4 In Vitro Diagnostics Market, Netherlands, Category Contribution (%), 2009 20

3.5 In Vitro Diagnostics, Netherlands, Company Share (2008-2009) 26

4 Clinical Chemistry In Netherlands 28

4.1 Clinical Chemistry, Market Segmentation 28

4.2 Clinical Chemistry Market, Netherlands, Revenue Mix ($m), 2009 29

4.3 Clinical Chemistry Market, Netherlands, Category Contribution (%), 2009 30

4.4 Clinical Chemistry Overall Revenue (2002-2016) 31

4.4.1 Clinical Chemistry Analyzers Revenue (2002-2016) 35

4.4.2 Urine Analysis Revenue (2002-2016) 39

4.5 Clinical Chemistry Distribution Share (2008-2009) 43

4.6 Clinical Chemistry, Netherlands, Company Share (2008-2009) 44

5 Genetic Testing In Netherlands 46

5.1 Genetic Testing, Market Segmentation 46

5.2 Genetic Testing Market, Netherlands, Revenue Mix ($m), 2009 47

5.3 Genetic Testing Market, Netherlands, Category Contribution (%), 2009 48

5.4 Genetic Testing Overall Revenue (2002-2016) 49

5.5 Genetic Testing Distribution Share (2008-2009) 53

5.6 Genetic Testing, Netherlands, Company Share (2008-2009) 54

6 Haematology In Netherlands 55

6.1 Haematology, Market Segmentation 55

6.2 Heamatology Market, Netherlands, Revenue Mix ($m), 2009 56

6.3 Haematology Market, Netherlands, Category Contribution (%), 2009 57

6.4 Haematology Overall Revenue (2002-2016) 58

6.4.1 Haematology Reagnets Revenue (2002-2016) 62

6.4.2 Immunohaematology Revenue (2002-2016) 66

6.4.3 Haemostasis Revenue (2002-2016) 70

6.4.4 Haematology Rapid Tests Revenue (2002-2016) 74

6.4.5 Haematology Cell Counters Revenue (2002-2016) 78

6.5 Haematology Distribution Share (2008-2009) 82

6.6 Haematology, Netherlands, Company Share (2008-2009) 83

7 Histology And Cytology In Netherlands 85

7.1 Histology and Cytology, Market Segmentation 85

7.2 Histology and Cytology Market, Netherlands, Revenue Mix ($m), 2009 86

7.3 Histology and Cytology Market, Netherlands, Category Contribution (%), 2009 87

7.4 Histology and Cytology Overall Revenue (2002-2016) 88

7.4.1 Histology Revenue (2002-2016) 92

7.5 Histology And Cytology Distribution Share (2008-2009) 96

7.6 Histology And Cytology, Netherlands, Company Share (2008-2009) 97

8 Immuno Chemistry In Netherlands 99

8.1 Immuno Chemistry, Market Segmentation 99

8.2 Immuno Chemistry Market, Netherlands, Revenue Mix ($m), 2009 100

8.3 Immuno Chemistry Market, Netherlands, Category Contribution (%), 2009 101

8.4 Immuno Chemistry Overall Revenue (2002-2016) 102

8.4.1 Disease Specific Immunochemistry Revenue (2002-2016) 106

8.4.2 Drug Related Testing Revenue (2002-2016) 110

8.4.3 Endocrinology Tests Revenue (2002-2016) 114

8.4.4 Immunochemistry Analyzers Revenue (2002-2016) 118

8.5 Immuno Chemistry Distribution Share (2008-2009) 122

8.6 Immuno Chemistry, Netherlands, Company Share (2008-2009) 123

9 Infectious Immunology In Netherlands 125

9.1 Infectious Immunology, Market Segmentation 125

9.2 Infectious Immunology Market, Netherlands, Revenue Mix ($m), 2009 126

9.3 Infectious Immunology Market, Netherlands, Category Contribution (%), 2009 127

9.4 Infectious Immunology Overall Revenue (2002-2016) 128

9.5 Infectious Immunology Distribution Share (2008-2009) 132

9.6 Infectious Immunology, Netherlands, Company Share (2008-2009) 133

10 Microbiology Culture In Netherlands 135

10.1 Microbiology Culture, Market Segmentation 135

10.2 Microbiology Culture Market, Netherlands, Revenue Mix ($m), 2009 136

10.3 Microbiology Culture Market, Netherlands, Category Contribution (%), 2009 137

10.4 Microbiology Culture Overall Revenue (2002-2016) 138

10.4.1 Microbiology Analyzers Revenue (2002-2016) 142

10.5 Microbiology Culture Distribution Share (2008-2009) 146

10.6 Microbiology Culture, Netherlands, Company Share (2008-2009) 147

11 Overview of Key Companies in Netherlands In Vitro Diagnostics Market 149

11.1 F. Hoffmann-La Roche Ltd. 149

11.1.1 Company Overview 149

11.1.2 Share in the Netherlands In Vitro Diagnostics Market 149

11.2 Siemens Healthcare 151

11.2.1 Company Overview 151

11.2.2 Share in the Netherlands In Vitro Diagnostics Market 151

11.3 Abbott Laboratories 152

11.3.1 Company Overview 152

11.3.2 Share in the Netherlands In Vitro Diagnostics Market 152

11.4 bioMerieux S.A. 153

11.4.1 Company Overview 153

11.4.2 Share in the Netherlands In Vitro Diagnostics Market 153

11.5 Beckman Coulter, Inc. 154

11.5.1 Company Overview 154

11.5.2 Share in the Netherlands In Vitro Diagnostics Market 154

11.6 Ortho-Clinical Diagnostics Inc. 155

11.6.1 Company Overview 155

11.6.2 Share in the Netherlands In Vitro Diagnostics Market 155

11.7 Inverness Medical Innovations, Inc. 156

11.7.1 Company Overview 156

11.8 Becton, Dickinson and Company 156

11.8.1 Company Overview 156

11.9 Bio-Rad Laboratories, Inc. 157

11.9.1 Company Overview 157

11.10 Hologic, Inc. 157

11.10.1 Company Overview 157

11.11 OLYMPUS CORPORATION 158

11.11.1 Company Overview 158

11.12 Mindray Medical International Limited 158

11.12.1 Company Overview 158

11.13 Sysmex Corporation 158

11.13.1 Company Overview 158

11.14 Ventana Medical Systems, Inc. 159

11.14.1 Company Overview 159

11.15 DiaSorin S.p.A 159

11.15.1 Company Overview 159

11.16 Qiagen N.V. 159

11.16.1 Company Overview 159

11.17 Gen-Probe Incorporated 160

11.17.1 Company Overview 160

11.18 Phadia AB 160

11.18.1 Company Overview 160

11.19 Vital Scientific B.V. 160

11.19.1 Company Overview 160

11.20 Nucletron B.V. 161

11.20.1 Company Overview 161

11.21 Kreatech Holding B.V. 161

11.21.1 Company Overview 161

11.22 Nordic Immunological Laboratories 161

11.22.1 Company Overview 161

11.23 Agendia BV 162

11.23.1 Company Overview 162

11.24 Adamas Instrumenten bv 162

11.24.1 Company Overview 162

11.25 Be Kerkhof 162

11.25.1 Company Overview 162

12 In Vitro Diagnostics Market Pipeline Products 163

12.1 Clinical Chemistry Market Pipeline Products 163

12.2 Immuno Chemistry Market Pipeline Products 165

12.3 Haematology Market Pipeline Products 167

12.4 Infectious Immunology Market Pipeline Products 168

12.5 Microbiology Culture Market Pipeline Products 170

12.6 Histology and Cytology Market Pipeline Products 171

12.7 Genetic Testing Market Pipeline Products 172

13 Financial Deals Landscape 174

13.1 Partnerships 174

13.1.1 QIAGEN Enters Into Distribution Agreement With Celera 174

13.1.2 Sequenom Enters Into Licensing Agreement With Optherion 175

13.1.3 QIAGEN Enters Into Licensing Agreement With Johns Hopkins University 176

13.1.4 DiaGenic Enters Into Distribution Agreement With Ferrer inCode 177

13.1.5 OraSure Technologies Enters Into An Agreement With Roche Diagnostics 178

13.1.6 Royal Philips Electronics Enters Into An Agreement With bioMerieux 179

13.1.7 Technogenetics Signs Distribution Agreement With A. Menarini Diagnostics 180

13.1.8 Inverness Medical Innovations Enters Into Distribution Agreement With Epocal 182

13.1.9 Radient Pharmaceuticals Enters Into An Agreement With GenWay Biotech 183

13.1.10 Amsterdam Molecular Therapeutics Enters Into An Agreement With Progenika Biopharma 184

13.1.11 QIAGEN Enters Into An Agreement With Roche And Idaho Technology 185

13.1.12 Leica Microsystems Signs An Agreement With A. Menarini Diagnostics 186

14 Recent Developments 187

14.1 Strategy and Business Planning 187

14.1.1 Jun 17, 2010: QIAGEN Expands Partnership with Genome Diagnostics For Development Of New Tests For Applications In Prevention And Personalized Healthcare 187

14.1.2 Dec 08, 2009: Genetix Expands Sales, Support And Service Organization In France And Benelux 188

14.2 Government and Public Interest 188

14.2.1 Jun 28, 2010: Cheap, Simple, Noninvasive Blood Test May Replace Invasive Diagnostic Techniques In Early Pregnancy: Dutch Researchers 188

14.2.2 Mar 16, 2010: Home-Testing Kits Could Help To Detect HPV In Women Who Do Not Attend Cervical Screening 189

14.3 Product News 190

14.3.1 Jan 25, 2010: Qiagen Introduces QIAsymphony AS 190

14.3.2 Oct 29, 2009: Amsredam Molecular Therapeutics Enters An Agreement With Progenika To Develop LPL Chip 190

14.3.3 Sep 10, 2009: QIAGEN Introduces Artus Influenza/H1 RG/LC RT-PCR Kit 191

15 Appendix 193

15.1 Definitions of Markets Covered in the Report 194

15.1.1 In Vitro Diagnostics 194

15.2 Research Methodology 202

15.3 Secondary Research 203

15.4 Primary Research 203

15.5 Models 204

15.6 Forecasts 204

15.7 Expert Panels 204

15.8 GlobalData Consulting 204

15.9 Currency Conversion 205

15.10 Contact Us 205

15.11 Disclaimer 205

List of Tables

1.1 List of Tables

Table 1: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), 2002-2016 18

Table 2: In Vitro Diagnostics Market, Netherlands, Category Contribution (%), 2009 20

Table 3: In Vitro Diagnostics, Netherlands, Cross-Category Analysis, 2002-2016 21

Table 4: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), Historic, 2002-2009 23

Table 5: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), Forecast, 2009-2016 25

Table 6: In Vitro Diagnostics, Netherlands, Company Share by Revenue ($m), 2008-2009 27

Table 7: Clinical Chemistry, Netherlands, Category Contribution (%), 2009 30

Table 8: Clinical Chemistry, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 32

Table 9: Clinical Chemistry, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 34

Table 10: Clinical Chemistry Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 36

Table 11: Clinical Chemistry Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 38

Table 12: Urine Analysis, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 40

Table 13: Urine Analysis, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 42

Table 14: Clinical Chemistry, Netherlands, Distribution Share by Revenue ($m), 2008-2009 43

Table 15: Clinical Chemistry, Netherlands, Company Share by Revenue ($m), 2008-2009 45

Table 16: Genetic Testing Market, Netherlands, Category Contribution (%), 2009 48

Table 17: Genetic Testing, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 50

Table 18: Genetic Testing, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 52

Table 19: Genetic Testing, Netherlands, Distribution Share by Revenue ($m), 2008-2009 53

Table 20: Genetic Testing, Netherlands, Company Share by Revenue ($m), 2008-2009 54

Table 21: Haematology Market, Netherlands, Category Contribution (%), 2009 57

Table 22: Haematology, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 59

Table 23: Haematology, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 61

Table 24: Haematology Reagents, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 63

Table 25: Haematology Reagents, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 65

Table 26: Immunohaematology, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 67

Table 27: Immunohaematology, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 69

Table 28: Haemostasis, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 71

Table 29: Haemostasis, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 73

Table 30: Haematology Rapid Tests, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 75

Table 31: Haematology Rapid Tests, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 77

Table 32: Haematology Cell Counters, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 79

Table 33: Haematology Cell Counters, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 81

Table 34: Haematology, Netherlands, Distribution Share by Revenue ($m), 2008-2009 82

Table 35: Haematology, Netherlands, Company Share by Revenue ($m), 2008-2009 84

Table 36: Histology and Cytology Market, Netherlands, Category Contribution (%), 2009 87

Table 37: Histology And Cytology, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 89

Table 38: Histology And Cytology, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 91

Table 39: Histology, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 93

Table 40: Histology, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 95

Table 41: Histology And Cytology, Netherlands, Distribution Share by Revenue ($m), 2008-2009 96

Table 42: Histology And Cytology, Netherlands, Company Share by Revenue ($m), 2008-2009 98

Table 43: Immuno Chemistry Market, Netherlands, Category Contribution (%), 2009 101

Table 44: Immuno Chemistry, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 103

Table 45: Immuno Chemistry, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 105

Table 46: Disease Specific Immunochemistry, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 107

Table 47: Disease Specific Immunochemistry, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 109

Table 48: Drug Related Testing, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 111

Table 49: Drug Related Testing, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 113

Table 50: Endocrinology Tests, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 115

Table 51: Endocrinology Tests, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 117

Table 52: Immunochemistry Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 119

Table 53: Immunochemistry Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 121

Table 54: Immuno Chemistry, Netherlands, Distribution Share by Revenue ($m), 2008-2009 122

Table 55: Immuno Chemistry, Netherlands, Company Share by Revenue ($m), 2008-2009 124

Table 56: Infectious Immunology Market, Netherlands, Category Contribution (%), 2009 127

Table 57: Infectious Immunology, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 129

Table 58: Infectious Immunology, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 131

Table 59: Infectious Immunology, Netherlands, Distribution Share by Revenue ($m), 2008-2009 132

Table 60: Infectious Immunology, Netherlands, Company Share by Revenue ($m), 2008-2009 134

Table 61: Microbiology Culture Market, Netherlands, Category Contribution (%), 2009 137

Table 62: Microbiology Culture, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 139

Table 63: Microbiology Culture, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 141

Table 64: Microbiology Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 143

Table 65: Microbiology Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 145

Table 66: Microbiology Culture, Netherlands, Distribution Share by Revenue ($m), 2008-2009 146

Table 67: Microbiology Culture, Netherlands, Company Share by Revenue ($m), 2008-2009 148

Table 68: Clinical Chemistry Market Pipeline Products 163

Table 69: Immuno Chemistry Market Pipeline Products 165

Table 70: Haematology Market Pipeline Products 167

Table 71: Infectious Immunology Market Pipeline Products 168

Table 72: Microbiology Culture Market Pipeline Products 170

Table 73: Histology and Cytology Market Pipeline Products 171

Table 74: Genetic Testing Market Pipeline Products 172

Table 75: QIAGEN Enters Into Distribution Agreement With Celera 174

Table 76: Sequenom Enters Into Licensing Agreement With Optherion 175

Table 77: QIAGEN Enters Into Licensing Agreement With Johns Hopkins University 176

Table 78: DiaGenic Enters Into Distribution Agreement With Ferrer inCode 177

Table 79: OraSure Technologies Enters Into An Agreement With Roche Diagnostics 178

Table 80: Royal Philips Electronics Enters Into An Agreement With bioMerieux 179

Table 81: Technogenetics Signs Distribution Agreement With A. Menarini Diagnostics 180

Table 82: Inverness Medical Innovations Enters Into Distribution Agreement With Epocal 182

Table 83: Radient Pharmaceuticals Enters Into An Agreement With GenWay Biotech 183

Table 84: Amsterdam Molecular Therapeutics Enters Into An Agreement With Progenika Biopharma 184

Table 85: QIAGEN Enters Into An Agreement With Roche And Idaho Technology 185

Table 86: Leica Microsystems Signs An Agreement With A. Menarini Diagnostics 186

Table 87: USD to Local Currency, Netherlands, Average Actual Rate 2002-2009 205

List of Figures

1.2 List of Figures

Figure 1: In Vitro Diagnostics, Market Segmentation 16

Figure 2: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), 2002-2016 17

Figure 3: In Vitro Diagnostics Market, Netherlands, Revenue Mix ($m), 2009 19

Figure 4: In Vitro Diagnostics Market, Netherlands, Category Contribution (%), 2009 20

Figure 5: In Vitro Diagnostics, Netherlands, Cross-Category Analysis, 2002-2016 21

Figure 6: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), Historic, 2002-2009 22

Figure 7: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), Forecast, 2009-2016 24

Figure 8: In Vitro Diagnostics, Netherlands, Company Share (%), 2009 26

Figure 9: Clinical Chemistry, Market Segmentation 28

Figure 10: Clinical Chemistry Market, Netherlands, Revenue Mix ($m), 2009 29

Figure 11: Clinical Chemistry, Netherlands, Category Contribution (%), 2009 30

Figure 12: Clinical Chemistry, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 31

Figure 13: Clinical Chemistry, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 33

Figure 14: Clinical Chemistry Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 35

Figure 15: Clinical Chemistry Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 37

Figure 16: Urine Analysis, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 39

Figure 17: Urine Analysis, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 41

Figure 18: Clinical Chemistry, Netherlands, Company Share (%), 2009 44

Figure 19: Genetic Testing, Market Segmentation 46

Figure 20: Genetic Testing, Netherlands, Revenue Mix ($m), 2009 47

Figure 21: Genetic Testing, Netherlands, Category Contribution (%), 2009 48

Figure 22: Genetic Testing, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 49

Figure 23: Genetic Testing, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 51

Figure 24: Genetic Testing, Netherlands, Company Share (%), 2009 54

Figure 25: Haematology, Market Segmentation 55

Figure 26: Heamatology, Netherlands, Revenue Mix ($m), 2009 56

Figure 27: Haematology, Netherlands, Category Contribution (%), 2009 57

Figure 28: Haematology, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 58

Figure 29: Haematology, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 60

Figure 30: Haematology Reagents, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 62

Figure 31: Haematology Reagents, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 64

Figure 32: Immunohaematology, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 66

Figure 33: Immunohaematology, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 68

Figure 34: Haemostasis, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 70

Figure 35: Haemostasis, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 72

Figure 36: Haematology Rapid Tests, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 74

Figure 37: Haematology Rapid Tests, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 76

Figure 38: Haematology Cell Counters, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 78

Figure 39: Haematology Cell Counters, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 80

Figure 40: Haematology, Netherlands, Company Share (%), 2009 83

Figure 41: Histology and Cytology, Market Segmentation 85

Figure 42: Histology and Cytology, Netherlands, Revenue Mix ($m), 2009 86

Figure 43: Histology and Cytology, Netherlands, Category Contribution (%), 2009 87

Figure 44: Histology And Cytology, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 88

Figure 45: Histology And Cytology, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 90

Figure 46: Histology, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 92

Figure 47: Histology, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 94

Figure 48: Histology And Cytology, Netherlands, Company Share (%), 2009 97

Figure 49: Immuno Chemistry, Market Segmentation 99

Figure 50: Immuno Chemistry, Netherlands, Revenue Mix ($m), 2009 100

Figure 51: Immuno Chemistry, Netherlands, Category Contribution (%), 2009 101

Figure 52: Immuno Chemistry, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 102

Figure 53: Immuno Chemistry, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 104

Figure 54: Disease Specific Immunochemistry, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 106

Figure 55: Disease Specific Immunochemistry, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 108

Figure 56: Drug Related Testing, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 110

Figure 57: Drug Related Testing, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 112

Figure 58: Endocrinology Tests, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 114

Figure 59: Endocrinology Tests, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 116

Figure 60: Immunochemistry Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 118

Figure 61: Immunochemistry Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 120

Figure 62: Immuno Chemistry, Netherlands, Company Share (%), 2009 123

Figure 63: Infectious Immunology, Market Segmentation 125

Figure 64: Infectious Immunology, Netherlands, Revenue Mix ($m), 2009 126

Figure 65: Infectious Immunology, Netherlands, Category Contribution (%), 2009 127

Figure 66: Infectious Immunology, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 128

Figure 67: Infectious Immunology, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 130

Figure 68: Infectious Immunology, Netherlands, Company Share (%), 2009 133

Figure 69: Microbiology Culture, Market Segmentation 135

Figure 70: Microbiology Culture, Netherlands, Revenue Mix ($m), 2009 136

Figure 71: Microbiology Culture, Netherlands, Category Contribution (%), 2009 137

Figure 72: Microbiology Culture, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 138

Figure 73: Microbiology Culture, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 140

Figure 74: Microbiology Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 142

Figure 75: Microbiology Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 144

Figure 76: Microbiology Culture, Netherlands, Company Share (%), 2009 147

Figure 77: F. Hoffmann-La Roche Ltd., Company Share (%),Netherlands In Vitro Diagnostics Market, 2009 149

Figure 78: Siemens Healthcare, Company Share (%),Netherlands In Vitro Diagnostics Market, 2009 151

Figure 79: Abbott Laboratories, Company Share (%),Netherlands In Vitro Diagnostics Market, 2009 152

Figure 80: bioMerieux S.A., Company Share (%),Netherlands In Vitro Diagnostics Market, 2009 153

Figure 81: Beckman Coulter, Inc., Company Share (%),Netherlands In Vitro Diagnostics Market, 2009 154

Figure 82: Ortho-Clinical Diagnostics Inc., Company Share (%),Netherlands In Vitro Diagnostics Market, 2009 155

Figure 83: GlobalData Methodology 202

To order this report:

In Vitro Diagnostic Industry: Brazil In Vitro Diagnostics Market Outlook to 2016

In Vitro Diagnostic Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

21%

more press release views with 

Request a Demo